1 Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy Derek E. Thomas 1, Hristos Z. Kaimakliotis 1,2, Kevin R. Rice 1,2, Jose A. Pereira 1,2, Paul Johnston 1,2, Marietta L. Moore 1, Angela Reed 1, Dylan M. Cregar 1,2, Cindy Franklin 1,2, Rhoda L. Loman 1,2, Michael O. Koch 1,2, Richard Bihrle 1,2, Richard S. Foster 1,2, Timothy A. Masterson 1,2, Thomas A. Gardner 1,2, Chandru P. Sundaram 1,2, Charles R. Powell 1,2, Stephen D.W. Beck 1,2, David J. Grignon 1,3, Liang Cheng 1,3, Costantine Albany 1, and Noah M. Hahn 4 1 Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 2 Department of Urology, Indiana University School of Medicine, Indianapolis, IN 3 Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 4 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD Abstract HHS Public Access Author manuscript Published in final edited form as: Clin Genitourin Cancer August ; 15(4): doi: /j.clgc We performed a single-institution retrospective analysis of 137 patients with muscle-invasive urothelial carcinoma who underwent neoadjuvant chemotherapy and radical cystectomy to assess the prognostic significance of carcinoma in situ (CIS). The pathologic complete response rates were significantly decreased for patients with CIS identified on transurethral resection of the bladder tumor before treatment. The long-term follow-up data from patients with isolated CIS at cystectomy revealed prolonged progression-free and overall survival. Background Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. Materials and Methods Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response (pcr) rates stratified by TURBT CIS status were compared. The secondary analyses included tumor response, progression-free survival (PFS), Address for correspondence: Noah M. Hahn, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, The Bunting-Blaustein Cancer Research Building 1, Room 1M42, 1650 Orleans Street, Baltimore, MD Disclosure The authors declare that they have no competing interests.
2 Thomas et al. Page 2 overall survival (OS), and an exploratory post hoc analysis of patients with pathologic CIS only (ptisn0) at cystectomy. Results A total of 137 patients with MIUC were identified. TURBT CIS was noted in 30.7% of the patients. The absence of TURBT CIS was associated with a significantly increased pcr rate (23.2% vs. 9.5%; odds ratio, 4.08; 95% confidence interval, ; P =.025). Stage ptisn0 disease was observed in 19.0% of the TURBT CIS patients. TURBT CIS status did not significantly affect the PFS or OS outcomes. Post hoc analysis of the ptisn0 patients revealed prolonged median PFS (104.5 vs months; P =.055) and OS (104.5 vs months; P =. 091) outcomes similar to those for the pcr patients. Conclusion The absence of CIS on pretreatment TURBT in patients with MIUC undergoing NAC was associated with increased pcr rates, with no observed differences in PFS or OS. Isolated CIS at cystectomy was frequently observed, with lengthy PFS and OS durations similar to those for pcr patients. Further studies aimed at understanding the biology and clinical effect of CIS in MIUC are warranted. Keywords CIS; NAC; Pathologic complete response; Transurethral resection of bladder tumor; UC Introduction Urothelial carcinoma (UC) of the bladder is a common cancer, with > 76, 000 new cases diagnosed and 16,000 deaths annually in the United States. 1 Worldwide, an estimated 450,000 new cases and 165,000 deaths occur annually. 2 In muscle-invasive UC (MIUC), radical cystectomy remains a standard treatment approach with significant quality of life effects. Given the substantial morbidity from surgical intervention and metastatic relapse rates approaching 50%, the identification of clinical, pathologic, and molecular factors that affect patient outcomes is critical to the success of personalized patient care. 3 When observed, the presence of carcinoma in situ (CIS) has been associated with an aggressive, initially immunotherapy responsive phenotype. CIS has been shown to have a 54% to 83% risk of progression to MIUC if left untreated. 4,5 Additionally, extravesical involvement of UC is common with CIS and carries a worse prognosis. 6,7 Aggressive intravesical therapy after the initial resection of non muscle invasive UC (NMIUC) or cystectomy in patients developing relapse after adequate intravesical therapy has typically been recommended. 8 Uncertainty regarding the distinct mechanisms responsible for the improved response rates to local immunotherapy in patients with CIS compared with those with high-grade papillary NMIUC (< pt2) underscores the need for improved understanding of the underlying pathobiology of CIS. 9,10 In patients with UC, CIS can be present as an isolated finding or simultaneously in association with more invasive tumors within the bladder and upper urinary tract. A study by Shariat et al 11 noted significantly increased disease recurrence when CIS was identified on cystectomy specimens performed for NMIBC. Another study by Gupta et al 12 revealed increased recurrence rates and decreased cancer-specific survival (CSS) in patients with
3 Thomas et al. Page 3 NMIBC treated with cystectomy if CIS had been identified on precystectomy transurethral resection of bladder tumor (TURBT) samples. 12 A meta-analysis by Sylvester et al 13 also showed that the presence of concurrent CIS within stage Ta or T1 TURBT specimens correlated with significantly increased risks of disease recurrence and progression. Two large retrospective studies attempted to evaluate whether CIS has prognostic significance specifically in patients with MIUC. Yafi et al 14 found that CIS found on TURBT in patients with MIUC led to statistically significant upstaging at cystectomy; however, no significant differences in progression-free survival (PFS), CSS, or overall survival (OS) were observed. Nuhn et al 15 evaluated MIUC cystectomy specimens for the presence of CIS and found no associated differences in PFS or CSS. Level 1 evidence from randomized clinical trials demonstrated significant improvements in OS with the use of neoadjuvant cisplatin-based combination chemotherapy before cystectomy for eligible patients with MIUC. 16,17 Furthermore, the neoadjuvant approach represents an attractive setting for drug development, because multiple studies have demonstrated an association between the pathologic response and longer term survival outcomes In general, agreement exists that a reduction in stage to a non muscleinvasive stage (< pt2n0) confers more favorable outcomes. It is less clear whether a pathologic complete response (pcr), defined as no evidence of any tumor of any stage (pt0n0), is necessary for patient benefit compared with simply a reduction to a non muscle-invasive stage. Because clinical trials now commonly use pcr as a primary endpoint for neoadjuvant MIUC trials, a thorough understanding of the baseline patient factors with an effect on pcr rates is critical. In the only study to analyze the effect of TURBT CIS on the cystectomy pathologic response in MIUC patients who received neoadjuvant chemotherapy (NAC), Parker et al 21 reported inferior pcr rates at cystectomy in association with TURBT CIS; however, no effect on survival outcomes was observed. We present the results from our large single-institution retrospective analysis evaluating the pathologic and prognostic significance of pretreatment TURBT CIS in patients with MIUC treated with NAC followed by cystectomy. Materials and Methods Study Cohort The study subjects were identified from the urology and medical oncology department clinical databases of Indiana University Simon Cancer Center (IUSCC). The eligibility criteria included patients of any age with nonmetastatic UC who were documented to have received NAC and whose pathologic reports were available for both prechemotherapy TURBT (or staging biopsy) and post-chemotherapy cystectomy. Patients with clinical lymph node-positive disease found on imaging studies were included as long as NAC and cystectomy had been performed with curative intent. Subjects with components of non small-cell variant histologic features were allowed; however, subjects with pure nonurothelial histologic features found on TURBT were excluded. Subjects with NMIUC and those with any component of small cell or neuroendocrine features on TURBT were excluded. The institutional review board of the IUSCC approved the present study.
4 Thomas et al. Page 4 Pathologic Staging and Response Evaluation Clinical Data Evaluation All cystectomies were performed at the IUSCC (Indianapolis, IN). All TURBTs and cystectomy pathologic specimens obtained at IUSCC were reviewed by expert genitourinary pathologists. The slides from TURBTs performed at outside institutions were not uniformly reviewed again, and staging was established by a review of the outside pathology reports. Pathologic staging was performed in accordance with the American Joint Committee on Cancer TNM system for UC of the bladder. A pcr was defined by a finding of T0N0 at cystectomy. The available clinical and demographic information was recorded for all study subjects and included the following: age at TURBT, gender, race, Eastern Cooperative Oncology Group performance status, Karnofsky performance status, baseline laboratory values (creatinine, white blood cell count, hemoglobin, platelet count), TURBT date, clinical stage (including TURBT pathologic findings and other staging diagnostics), presence of variant histologic features on TURBT (types and percentages, if reported), the presence of CIS on TURBT, NAC regimen, cycles of NAC completed, cystectomy date, pathologic stage, date of progression, date of death, and date of the last follow-up visit. The data were tabulated into a clinical database for further statistical analyses (Figure 1). All primary information was gathered from the IUSCC and associated hospital electronic medical record systems. Data Verification and Missing Data Methods Survival Evaluation Statistical Analysis The clinical information, including the pathologic reports and stage, was verified by all investigators for accuracy. For the TURBT cases from outside institutions, which were reviewed by IUSCC pathologists, the IUSCC pathology review date was used as the TURBT date if the original TURBT date was not available from the outside institution pathology report. If the original TURBT date was supplied, the original TURBT date was used in all analyses. PFS was calculated as the duration between the TURBT date and the occurrence of either death from any cause or documented UC recurrence radiographically or clinically. OS was calculated as the duration between the TURBT date and death from any cause. For both PFS and OS analyses, patients lost to follow-up were censored at their last known follow-up date. The primary outcome of interest in our analysis was the pcr rate. We aimed to test the experimental hypothesis that the finding of CIS in TURBT samples from MIUC patients would be associated with lower pcr rates after NAC. All baseline clinical variables for which data were complete (age at TURBT, gender, race, clinical stage, NAC regimen, presence of variant histologic features, CIS on TURBT) were evaluated by logistic regression analyses for associations with the pcr rate, with the significance level set at P <. 05. Continuous variables (ie, age at TURBT) were dichotomized according to the median values. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for all
5 Thomas et al. Page 5 Results Patient Population NAC Tumor Response variables analyzed. The secondary outcomes included comparisons of PFS and OS according to TURBT CIS status. Kaplan-Meier curves were calculated and log-rank analyses used to compare the PFS and OS according to TURBT CIS status and according to pathologic ptis status. χ 2 Tests and Student tests were used to assess the differences in baseline demographic variables between patients with and without CIS on TURBT. χ 2 Tests were used in exploratory analyses to identify the baseline factors predictive of ptisn0 status. All analyses were performed using SPSS Statistics, version 22. After database review, 152 potential subjects were identified. Of the 152 potential subjects, 6 with stage T1 NMIUC and 9 with small cell carcinoma or neuroendocrine features were excluded, leaving a final study data set of 137 subjects (Figure 2). The study data set was divided into 2 cohorts, with 42 subjects with CIS found on TURBT (30.7%) and 95 subjects without CIS found on TURBT. The patients had documented follow-up data available for an average of 25.4 months (range, months). The patient demographics are listed in Table 1. The study population was a largely white male population, with a mean age of 61.1 years (median, 62.0 years). Most patients had clinical stage T2N0, and 40 patients (29.2%) had clinical lymph node involvement. Cisplatin-based NAC was used in 113 patients (82.5%). The presence of variant histologic features was noted in 46 patients (33.6%). Subjects with CIS found on TURBT were more frequently women, had a greater incidence of clinical stage T2N0 disease, had a lower incidence of clinical lymph node-positive disease, and were more frequently treated with cisplatin NAC. However, none of these differences were statistically significant. The pcr rate at cystectomy was lower in patients with CIS found on TURBT (9.5% vs. 23.2%; P =.07; Table 2). Furthermore, a significantly greater frequency of ptisn0m0 stage was observed at cystectomy in patients with CIS found on TURBT (19.0% vs. 3.2%; P <. 01). The rates of < pt2n0m0, pn +, and pm1 disease were similar between the 2 groups. Binary and Multinomial Logistic Regression Analyses Complete data were available for age, TURBT CIS status, variant histologic status, race, gender, pre-nac clinical stage, and cisplatin NAC status. On binary logistic regression analysis of these variables, age 62 years (OR, 2.76; 95% CI, ; P =.035) and nonwhite race (OR, 6.37; 95% CI, ; P =.009) were statistically associated with increased pcr rates. The absence of CIS on TURBT approached a statistical association with increased pcr rates (OR, 2.86; 95% CI, ; P =.069). On multinomial logistic regression analysis, the absence of CIS on TURBT (OR, 4.08; 95% CI, ; P =. 025) and nonwhite race (OR, 6.05; 95% CI, ; P =.031) were significantly associated with increased pcr rates. Both age 62 years and pre-nac clinical stage T2N0 showed a trend toward statistical significance. The full results are summarized in Table 3.
6 Thomas et al. Page 6 Survival Analyses Discussion The mean follow-up duration for subjects with and without CIS found on TURBT was 31.0 months (range, months) and 22.4 months (range, months). The median PFS for the entire cohort was 20.0 months (95% CI, months), with a median OS of 33.8 months (95% CI, months). The median PFS (27.6 vs months) and OS (47.6 vs months) were both increased for patients with CIS present on TURBT; however, neither result was statistically significant on log-rank testing (P =.67 for PFS and P =.82 for OS). Both PFS and OS stratified by TURBT CIS status are depicted in Figure 3. Given the high percentage of patients with ptisn0m0 disease at cystectomy in patients with CIS found on pre-nac TURBT, an exploratory analysis of PFS and OS between the pcr and ptisn0m0 patients was performed. As depicted in Figure 4, the median PFS was and months (P =.055) and the median OS was and months (P =.091) for pcr and ptisn0m0 patients, respectively. MIUC remains a frequent clinical dilemma with significant treatment-associated morbidity, in addition to high relapse rates. The ability to identify patients with MIUC with a greater risk of treatment failure, relapse, and decreased survival could have numerous potential benefits. These theoretically could include designing future studies of more aggressive subsets of patients who might benefit from alternative treatment regimens, evaluating highrisk tumor profiles for a better understanding of the underlying biology of the disease, and detecting potential novel targets for therapy in high-risk patients. Higher primary tumor stage and nodal metastases are known risk factors in MIUC that affect survival and are reflected in the current staging system; however, these can be difficult to accurately assess before definitive therapy, somewhat limiting their usefulness in preoperative treatment decisions. 3 Additional factors affecting the risk of relapse in patients with MIUC that are not considered in the current staging system include primary tumor location at the bladder neck or ureterovesical junction (especially with associated hydroureteronephrosis), sarcomatoid, small cell, or micropapillary variant histologic features, and an abnormal immunophenotype for p53, Rb, or vascular endothelial growth factor. 18 The presence of CIS on pre-nac TURBT could be another potential risk-modifying feature in MIUC, because it has been shown to have negative prognostic implications in studies of UC, as discussed previously. Additionally, if found to be a risk-modifying feature of MIUC, pre-nac TURBT CIS could have clinical utility, because it is an objective finding identifiable by pretreatment pathologic examination. Thus, it could potentially guide further treatment decisions for these patients. Despite this, the presence of pre-nac TURBT CIS has received limited evaluation in MIUC. The results of our study revealed significantly decreased pcr rates at cystectomy among patients with pre-nac CIS in their TURBT samples. This finding is noteworthy, because pcr is a frequently used early endpoint in clinical trial designs in the NAC setting for MIUC. Our results are similar to the results previously reported by Parker et al. 21 Interestingly, the survival analysis showed that patients with TURBT CIS had numerically greater median PFS and OS outcomes; however, the differences were not statistically
7 Thomas et al. Page 7 significant. This was unexpected, because we hypothesized that TURBT CIS would not only result in decreased pcr rates but would also result in decreased PFS and OS. A potential explanation for the longer than expected PFS and OS for these patients could be the uncontrolled differences in clinical stage between our cohorts, because more patients in the TURBT CIS cohort had lower stage (T2) disease and more patients in the non CIS cohort had higher stage (lymph node-positive) disease. In addition, more patients in the TURBT CIS cohort received cisplatin-based treatment, which is the only chemotherapy regimen shown in prospective studies to improve survival. Finally, as hypothesized, differences in survival with residual disease might exist between patients with and without CIS. In addition to differing pcr rates, subjects with TURBT CIS demonstrated a sixfold increase in the rate of ptisn0m0 at cystectomy. In an exploratory post hoc analysis of PFS and OS among pcr versus ptisn0m0 patients, those achieving a pcr had numerically superior outcomes, although the difference was not statistically significant and PFS and OS were prolonged in both subsets. The number of patients analyzed (pcr, n = 26; ptisn0m0, n = 11) was extremely small. In their previous analysis, Parker et al 21 suggested that ptisn0m0 might behave more similarly to a pcr as a potential reason for the lack of a significant survival difference seen in their study. To the best of our knowledge, large previous efforts have not been performed to assess whether a true clinically significant difference exists in the outcomes between patients with pcr versus ptisn0m0 after NAC for MIUC. Given the prolonged median PFS and OS in both groups in our study and the lack of significant survival outcome differences in the study by Parker et al, 21 further prospective evaluations of survival outcomes of patients with pcr versus ptisn0m0 are warranted. It is difficult to make a definitive conclusions, given the retrospective nature of our study, small sample size, and post hoc analysis. However, if ptisn0m0 truly results in prolonged survival, this is a critical finding, given that the current standard endpoint in NAC clinical trials is the pcr. Our analysis demonstrated a markedly increased pcr rate in nonwhite patients with MIUC treated with NAC. It is plausible that different races might have different tumor biology as an explanatory factor. However, caution is warranted in making any definitive conclusions from this finding owing to the extremely small number of nonwhite patients treated in our cohort. The strengths of our study included the number of NAC MIUC patients evaluated, the use of an objective preoperative variable (ie, the presence vs. absence of TURBT CIS), an objective postoperative endpoint (ie, pcr), cystectomy pathology reports assessed by similarly trained genitourinary pathologists at a single institution, the high overall rate of cisplatin-based regimens received, cystectomies performed by similarly trained urologists at a single institution, and the inclusion only of patients who had received NAC. Despite these strengths, a number of limitations must be acknowledged. Our study was limited to a single institution; thus, the patient outcomes could have been subject to institutional practice patterns, which might vary from the patterns of care in other geographic regions of the United States. Furthermore, the study was a retrospective evaluation spanning > 2 decades. Significant changes in care and management of UC have occurred (eg, an increased use of bacillus Calmette-Guérin in NMIUC, the documented benefit of NAC in MIUC, an
8 Thomas et al. Page 8 Conclusion References increased use of extended lymph node dissection), which might have introduced unaccounted-for confounding variables affecting the clinical outcomes. Although unexpected, the fairly large discrepancy among the clinical stages among our cohorts represents another limitation. However, we attempted to control for this on multivariate analysis. A potential reason for the presence of more clinically limited stage tumors in the TURBT CIS cohort might be related to the knowledge of CIS as a high-risk feature, combined with closer surveillance for NMIUC patients, leading to early recognition of MIUC in these patients. Another limitation was the inherent sampling error and tumor heterogeneity, which can make the identification of TURBT CIS difficult, in addition to the less judicious reporting of CIS in the past. Thus, 3 patients were found to have ptisn0m0 at cystectomy in the non-cis cohort, likely representing TURBT CIS that was not sampled on the initial biopsy or pathologic assessment. If the finding of CIS is truly prognostic or predictive, a more thorough and standardized evaluation of TURBT specimens and the use of improved techniques of identifying CIS would be advisable. Two such techniques include blue light and narrow band cystoscopy, both of which have been shown to improve the detection of CIS in NMIUC compared with traditional white light cystoscopy Finally, our survival analyses were limited by the variable follow-up durations and considerable number of patients censored with an unknown event status. Our study identified a significant association between the presence of CIS within the pretreatment TURBT sample of MIUC patients treated with NAC and decreased pcr rates at cystectomy. An analysis of survival outcomes, albeit limited by the small retrospective sample sizes, did not show an associated decrease in survival outcomes in association with TURBT CIS histologic features. Furthermore, the finding of ptisn0m0 at cystectomy is common in patients with CIS found on pre-nac TURBT samples. The clinical consequence of this finding remains undefined, although our data suggest the survival outcomes for these patients might be prolonged. Further delineation of any significant difference between ptisn0m0 and pcr outcomes will likely require prospective validation through large international data registries. Further study of patients with CIS could offer opportunities for improved translational study, which might have important clinical ramifications for both NMIUC and MIUC patients. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, CA Cancer J Clin. 2015; 65:5 29. [PubMed: ] 2. Sauter, G. Bladder cancer. In: Stewart, B., Wild, C., editors. World Cancer Report Lyon, France: WHO Press; Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55: [PubMed: ] 4. Lamm D, Herr H, Jakse G, et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol. 1998; 4: [PubMed: ] 5. Skinner DG, Richie JP, Cooper PH, Waisman J, Kaufman JJ. The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol. 1974; 112: [PubMed: ]
9 Thomas et al. Page 9 6. Chade DC, Shariat SF, Godoy G, et al. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010; 184: [PubMed: ] 7. Solsona E, Iborra I, Ricos JV, Monros JL, Dumont R, Almenar S. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol. 1996; 155: [PubMed: ] 8. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update Eur Urol. 2013; 64: [PubMed: ] 9. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000; 163: [PubMed: ] 10. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005; 174: [PubMed: ] 11. Shariat SF, Palapattu GS, Karakiewicz PI, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007; 51: [PubMed: ] 12. Gupta A, Lotan Y, Bastian PJ, et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008; 71: [PubMed: ] 13. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49: [PubMed: ] 14. Yafi FA, Aprikian AG, Chin JL, et al. Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol. 2014; 32: [PubMed: ] 15. Nuhn P, Bastian PJ, Novara G, et al. Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int. 2011; 87:42 8. [PubMed: ] 16. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48: [PubMed: ] 17. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: [PubMed: ] 18. Millikan R, Siefker-Radtke A, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol Oncol. 2003; 21: [PubMed: ] 19. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscleinvasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014; 32: [PubMed: ] 20. Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009; 115: [PubMed: ] 21. Parker WP, Ho PL, Melquist JJ, et al. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival. J Urol. 2015; 193: [PubMed: ] 22. Colombo R, Naspro R, Bellinzoni P, et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther Clin Risk Manag. 2007; 3: [PubMed: ] 23. Geavlete B, Jecu M, Multescu R, Geavlete P. Narrow-band imaging cystoscopy in non-muscleinvasive bladder cancer: a prospective comparison to the standard approach. Ther Adv Urol. 2012; 4: [PubMed: ]
10 Thomas et al. Page Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004; 171: [PubMed: ] 25. Ye Z, Hu J, Song X, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscleinvasive bladder cancer: a prospective, randomized and multi-center study. Sci Rep. 2015; 5: [PubMed: ]
11 Thomas et al. Page 11 Clinical Practice Points CIS in isolation or when identified with invasive urothelial cancer has been shown in multiple studies to have poor prognostic implications. CIS identified in pretreatment biopsy samples of patients treated with NAC results in decreased pcr rates at cystectomy; however, no significant differences in median PFS or OS were found. Among patients with CIS found on pretreatment biopsies, significant proportions of cystectomy samples revealed CIS only after NAC. Residual CIS at cystectomy resulted in prolonged median PFS and OS that were not significantly different from the median PFS and OS found with a pcr. Judicious evaluation and reporting of associated CIS should be performed to further understand the prevalence and prognostic significance of this finding. Further studies with the aim of understanding the underlying biology of CIS, given its differing clinical behavior, are warranted.
12 Thomas et al. Page 12 Figure 1. Schema Abbreviations: CIS = carcinoma in situ; MIUC = muscle-invasive urothelial carcinoma; pcr = pathologic complete response; TURBT = transurethral resection of bladder tumor.
13 Thomas et al. Page 13 Figure 2. Analysis Cohort Selection Abbreviations: NAC = neoadjuvant chemotherapy; NE = neuroendocrine; Pts = patients.
14 Thomas et al. Page 14 Figure 3. Survival According to Transurethral Resection of Bladder Tumor (TURBT) Carcinoma In Situ (CIS) Status. (A) Progression-free Survival (PFS). (B) Overall Survival (OS) Abbreviation: CI = confidence interval.
15 Thomas et al. Page 15 Figure 4. Survival According to Pathologic Complete Response (pcr) Versus ptisn0m0 Status. (A) Progression-free Survival (PFS). (B) Overall Survival (OS) Abbreviation: CI = confidence interval.
16 Thomas et al. Page 16 Table 1 Patient Demographics Variable Full Cohort (n = 137) CIS TURBT (n = 42) No CIS TURBT (n = 95) P Value Age (y) 61.1 ± ± ± Creatinine (mg/dl) 1.2 ± ± ± WBC count (K/mL) 7.5 ± ± ± Hemoglobin (g/dl) 13.0 ± ± ± Platelet count (K/mL) ± ± ± CIS on TURBT 42 (30.7) NA NA NA Variant histologic features 46 (33.6) 16 (38.1) 30 (31.6).46 ECOG PS (18.2) 6 (14.3) 19 (20.0) 1 27 (19.7) 6 (14.3) 21 (22.1) 2 5 (3.6) 3 (7.1) 2 (2.1) Unknown 80 (58.4) 27 (64.3) 53 (55.8) White race 128 (93.4) 40 (95.2) 88 (92.6).57 Male gender 104 (75.9) 29 (69.0) 75 (78.9).21 Clinical stage T2N0 83 (60.6) 30 (71.4) 53 (55.8).08 T3-T4N0 14 (10.2) 4 (9.5) 10 (10.5).86 Any T, N + 40 (29.2) 8 (19.0) 32 (33.7).08 Cisplatin-containing regimen 113 (82.5) 38 (90.5) 75 (78.9).10 Data presented as mean ± standard deviation or n (%). Abbreviations: CIS = carcinoma in situ; ECOG = Eastern Cooperative Oncology Group; PS = performance status; TURBT = transurethral resection of bladder tumor; WBC = white blood cell.
17 Thomas et al. Page 17 Table 2 Tumor Response at Cystectomy Outcome CIS TURBT (n = 42) No CIS TURBT (n = 95) P Value Complete response (pcr) 4 (9.5) 22 (23.2).07 Pathologic TisN0M0 8 (19.0) 3 (3.2) <.01 Pathologic <T2N0M0 18 (42.9) 35 (36.8).51 Pathologic N + M0 14 (33.3) 25 (26.3).40 Pathologic M1 0 (0.0) 2 (2.1) 1.00 Abbreviations: CIS = carcinoma in situ; pcr = pathologic complete response; TURBT = transurethral resection of bladder tumor.
18 Thomas et al. Page 18 Table 3 Logistic Regression Analysis Results of pcr Rate Stratified by Precystectomy Clinical Variables Binary LR Analysis Multinomial LR Analysis OR (95% CI) P Value OR (95% CI) P Value Variable Patients With pcr/total Age group >62 y 7/64 (10.9) Ref Ref 62 y 19/73 (26.0) 2.76 ( ) 2.72 ( ) CIS found on TURBT Yes 4/42 (9.5) Ref Ref No 22/95 (23.2) 2.86 ( ) 4.08 ( ) Variant histologic features Yes 10/46 (21.7) Ref Ref No 16/91 (17.6) 0.77 ( ) 0.83 ( ) Race White 21/128 (16.4) Ref Ref Nonwhite 5/9 (55.6) 6.37 ( ) 6.05 ( ) Gender Male 19/104 (18.3) Ref Ref Female 7/33 (21.2) 1.20 ( ) 0.81 ( ) Clinical stage T3-T4N + found on TURBT 7/54 (13.0) Ref Ref T2N0 found on TURBT 19/83 (22.9) 1.91 ( ) 2.78 ( ) Cisplatin-containing regimen Yes 24/113 (21.2) Ref Ref No 2/24 (8.3) 0.34 ( ) 0.38 ( ) Data presented as n (%). Abbreviations: CI = confidence interval; CIS = carcinoma in situ; LR = logistic regression; OR = odds ratio; pcr = pathologic complete response; Ref = reference group; TURBT = transurethral resection of bladder tumor.
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI
The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti
Case Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma
Review Special Issue: Bladder Cancer TheScientificWorldJOURNAL (2011) 11, 283 288 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2011.29 Role of Re-Resection in Non Muscle-Invasive Bladder Cancer Harry W.
A CME Webcast/TELECONFERENCE Case by Case: CRITICAL ISSUES IN SUPERFICIAL BLADDER CANCER MANAGEMENT An Interactive Case Format with Instant Audience Polling APRIL-MAY 2005 CME Program Slide Book Sponsored
VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) firstname.lastname@example.org
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
0022-5347/05/1741-0086/0 Vol. 174, 86 92, July 2005 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2005 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000162059.64886.1c BACILLUS CALMETTE-GUERIN
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? 1 M. Francesca Monn MD MPH# 1, Hristos Z Kaimakliotis MD# 1, K Clint Cary
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
UC San Francisco UC San Francisco Previously Published Works Title High-risk nonmuscle invasive bladder cancer: Definition and epidemiology Permalink https://escholarship.org/uc/item/11p2k07q Journal Current
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
EUROPEAN UROLOGY 64 (213) 37 313 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
Radiochemotherapy after Transurethral Resection is an Effective Treatment Method in T1G3 Bladder Cancer Z. AKÇETIN 1, J. TODOROV 1, E. TÜZEL 1, D.G. ENGEHAUSEN 1, F.S. KRAUSE 1, R. SAUER 2, K.M. SCHROTT
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
European Urology European Urology 42 (2002) 542±546 Beware the BCG Failures: A Review of One Institution's Results C. Richard W. Lockyer a,*, James E.C. Sedgwick b, David A. Gillatt a a Bristol Urological
ORIGINAL ARTICLE Vol. 41 (1): 30-39, January - February, 2015 doi: 10.1590/S1677-5538.IBJU.2015.01.06 Risk groups in bladder cancer patients treated with radical cystectomy Eva Mallen 1, Pedro Gil 2, Maria
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
ORIGINAL ARTICLE Vol. 41 (1): 30-39, January - February, 2015 doi: 10.1590/S1677-5538.IBJU.2015.01.06 Risk groups in bladder cancer patients treated with radical cystectomy Eva Mallen 1, Pedro Gil 2, Maria
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy Stephen H. Culp,*, Rian J. Dickstein,*, H. Barton Grossman, Shanna M. Pretzsch,* Sima Porten,* Siamak Daneshmand, Jie Cai,*
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
with metastatic breast and colorectal cancer who are treated with chemotherapy. In breast, lung and colorectal cancer, the value of early chemotherapy in operable localized and locally advanced disease
2885 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(15): 2885-2891. doi: 10.7150/jca.20003 Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT:
ORIGINAL ARTICLE Vol. 43 (x): 2017 August 8.[Ahead of print] doi: 10.1590/S1677-5538.IBJU.2017.0218 Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes Muammer
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National
Thomas Jefferson University Jefferson Digital Commons Department of Urology Faculty Papers Department of Urology 7-2014 Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined
Kobayashi et al. BMC Urology 2014, 14:5 RESEARCH ARTICLE Open Access Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology ASSOCIATION OF AGE WITH OUTCOMES OF UPPER TRACT UROTHELIAL CARCINOMA SHARIAT ET AL. BJUI BJU INTERNATIONAL Advanced patient age is associated
Putting NICE guidance into practice Costing report: Bladder cancer Implementing the NICE guideline on bladder cancer (NG2) Published: February 2015 Updated September 2015 to update the unit cost of transurethral
Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma
Original Article Quality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy Guru Sonpavde, MD 1 ; Bryan H. Goldman,
Bladder Cancer Organ-Sparing Approaches SAMO Interdisciplinary Workshop on Urogenital Tumors September 15, 2012 Daniel R. Zwahlen, MD Radiation Oncology Breast cancer Can I still keep my breast? History
RITE Thermochemotherapy in the treatment of BCG refractory NMIBC Ben Ayres Consultant Urological Surgeon St George s Hospital London 1 Financial and Other Disclosures Off-label use of drugs, devices, or
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of intravesical microwave hyperthermia with intravesical chemotherapy for superficial
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 email@example.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy Giuseppe Simone, Marco Bianchi, Diana Giannarelli, Siamak Daneshmand, Rocco
Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th
Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
Review Article Accuracy of endoscopic ultrasound staging for T2N0 esophageal cancer: a national cancer database analysis Ravi Shridhar 1, Jamie Huston 2, Kenneth L. Meredith 2 1 Department of Radiation
THE INTERNATIONAL CONFERENCE PROGRESS IN URO-ONCOLOGY 5th Edition September, 25th 26th 2014 CLUJ-NAPOCA Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life. Dr.
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
Urologic Oncology: Seminars and Original Investigations 30 (2012) 518 523 Seminar article Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer Bas W.G. van Rhijn,